Key result
Ciraparantag is a promising synthetic small molecule that inactivates heparins and DOACs, offering a potential universal reversal strategy compared to currently available agents.
Why the study?
Bleeding remains an important side effect of anticoagulants, and a universal reversal agent for life-threatening bleeding or emergency surgery is not yet available.
Ciraparantag is a promising synthetic small molecule under investigation as a universal reversal agent for heparins and DOACs.
Answers are grounded in this paper and cite their sources.
Does not support changing current reversal practices; leaves open a universal strategy pending randomized trials.
Despite the improved safety-profile of direct oral anticoagulants (DOACs), bleeding complications remain an important side effect of anticoagulant treatment. Although anticoagulant-specific antidotes are available, an universal anticoagulant reversal agent in case of life-threatening bleeding or emergency surgery is not yet available. Ciraparantag, a synthetic small molecule that inactivates heparins and DOAC, is a promising new reversal agent that has been investigated in phase 2 trials. In this short review we provide an overview of the preclinical and clinical evidence of ciraparantag, and compare strengths and weaknesses of ciraparantag and the currently available anticoagulant reversal strategies.
No takes yet. Share an insight, caveat, or question.
Leentjens et al. (2022) conducted a review in Bleeding complications of anticoagulant treatment. Ciraparantag vs. Currently available anticoagulant reversal strategies was evaluated. Ciraparantag is a promising synthetic small molecule that inactivates heparins and DOACs, offering a potential universal reversal strategy compared to currently available agents.
Synapse has enriched 10 related papers. Consider them for comparative context: